Symbiomix Therapeutics is a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections than can have serious health consequences. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world’s leading healthcare venture capital firms: OrbiMed, F-Prime Capital Partners, and HBM Partners. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.